PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...
"The consistency of treatment effect across disease locations is important, as ileal Crohn's disease (CD) is highly correlated with negative long-term outcomes and the fact that the terminal ileum ...
We reviewed all colonoscopic procedures performed in the endoscopy center of Ajou University Hospital, which is a 1000-bed teaching hospital, between 1 January 2005 and 31 December 2005. Six ...
Maintenance therapy with subcutaneous infliximab was more effective than placebo regardless of disease location or segment ...
Palisade Bio, Inc. (NASDAQ: PALI) shares barely cleared breakeven Wednesday. The company, a clinical-stage biopharmaceutical concern developing next-generation, once-daily, oral PDE4 inhibitor ...
PALI-2108 is the first and only PDE4 inhibitor in development targeting the terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) to address ...
"The consistency of treatment effect across disease locations is important, as ileal Crohn's disease (CD) is highly correlated with negative long-term outcomes and the fact that the terminal ileum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback